SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy

被引：4
|
作者：
te Raa, Doreen [1 ]
Derks, Ingrid A. M. [1 ]
Luijks, Dieuwertje M. [1 ]
van Laar, Jacoline [1 ]
Monsuur, Hanneke [1 ]
Oldreive, Ceri [2 ]
Jethwa, Alexander [3 ,4 ]
Huellein, Jennifer [3 ,4 ]
Stankovic, Tatjana [2 ]
Zenz, Thorsten [5 ]
Van Oers, Marinus H. J. [1 ]
Kater, Arnon P. [1 ]
Eldering, Eric [1 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England
[3] Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany
[4] German Canc Res Ctr, Heidelberg, Germany
[5] Heidelberg Univ, Heidelberg, Germany
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.711.711
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
711
引用
收藏
页数：2
相关论文
共 50 条
  • [31] SF3B1 MUTATIONS, IGHV MUTATION STATUS AND ABNORMALITIES DETECTED BY GENOMIC ARRAYS DETERMINE PROGNOSIS IN CLL WITH NORMAL KARYOTYPE
    Vetro, C.
    Jeromin, S.
    Stengel, A.
    Haferlach, T.
    Kern, W.
    Haferlach, C.
    HAEMATOLOGICA, 2016, 101 : 440 - 440
  • [32] SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
    S Jeromin
    S Weissmann
    C Haferlach
    F Dicker
    K Bayer
    V Grossmann
    T Alpermann
    A Roller
    A Kohlmann
    T Haferlach
    W Kern
    S Schnittger
    Leukemia, 2014, 28 : 108 - 117
  • [33] SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
    Jeromin, S.
    Weissmann, S.
    Haferlach, C.
    Dicker, F.
    Bayer, K.
    Grossmann, V.
    Alpermann, T.
    Roller, A.
    Kohlmann, A.
    Haferlach, T.
    Kern, W.
    Schnittger, S.
    LEUKEMIA, 2014, 28 (01) : 108 - 117
  • [34] Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia
    Adema, Vera
    Khouri, Jack
    Ni, Ying
    Rogers, Heesun J.
    Kerr, Cassandra M.
    Awada, Hassan
    Nagata, Yasunobu
    Kuzmanovic, Teodora
    Advani, Anjali S.
    Gerds, Aaron T.
    Mukherjee, Sudipto
    Nazha, Aziz
    Saunthararajah, Yogen
    Madanat, Yazan
    Patel, Bhumika J.
    Sole, Francesc
    Nawrocki, Steffan T.
    Carew, Jennifer S.
    Sekeres, Mikkael A.
    Maciejewski, Jaroslaw P.
    Visconte, Valeria
    Carraway, Hetty E.
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 735 - 738
  • [35] Modulation of the Clonal Composition in Relapsed CLL: A Study Based on Targeted Deep-Sequencing of ATM, BIRC3, NOTCH1, POT1, SF3B1, SAMHD1 and TP53
    Jeromin, Sabine
    Kern, Wolfgang
    Schabath, Richard
    Alpermann, Tamara
    Nadarajah, Niroshan
    Meggendorfer, Manja
    Schnittger, Susanne
    Haferlach, Torsten
    Haferlach, Claudia
    BLOOD, 2015, 126 (23)
  • [36] Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53
    Zent, Clive S.
    Burack, W. Richard
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 119 - 124
  • [37] NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment
    Chiaretti, Sabina
    Marinelli, Marilisa
    Del Giudice, Ilaria
    Bonina, Silvia
    Gabrielli, Sara
    Piciocchi, Alfonso
    Messina, Monica
    Vignetti, Marco
    Rossi, Davide
    Di Maio, Valeria
    Mauro, Francesca Romana
    Guarini, Anna
    Gaidano, Gianluca
    Foa, Robin
    BLOOD, 2012, 120 (21)
  • [38] TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
    Dreger, Peter
    Schnaiter, Andrea
    Zenz, Thorsten
    Boettcher, Sebastian
    Rossi, Marianna
    Paschka, Peter
    Buehler, Andreas
    Dietrich, Sascha
    Busch, Raymonde
    Ritgen, Matthias
    Bunjes, Donald
    Zeis, Matthias
    Stadler, Michael
    Uharek, Lutz
    Scheid, Christof
    Hegenbart, Ute
    Hallek, Michael
    Kneba, Michael
    Schmitz, Norbert
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2013, 121 (16) : 3284 - 3288
  • [39] SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome
    Falantes, Jose F.
    Marquez-Malaver, Francisco J.
    Carrillo, Estrella
    Garcia Culebras, Marta
    Morales, Rosario
    Prats, Concepcion
    Vargas, Maria T.
    Caballero, Teresa
    Rodriguez-Arboli, Eduardo
    Espigado, Ildefonso
    Perez-Simon, Jose Antonio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (12): : E1059 - E1066
  • [40] SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients with Lower-Risk Myelodysplastic Syndrome
    Falantes, Jose F.
    Marquez-Malaver, Francisco J.
    Carrillo-Cruz, Estrella
    Morales-Camacho, Rosario M.
    Prats-Martin, Concepcion
    Caballero, Teresa
    Rodriguez Arboli, Eduardo
    Espigado, Ildefonso
    Perez-Simon, Jose A.
    BLOOD, 2022, 140 : 6920 - 6922
12345